BCMA CAR-T Pipeline Landscape B-cell Maturation Antigen (BCMA) as an antigen has been shown to be specifically expressed in myeloma cells. With the ASH Annual Meeting 2019 close at hand, we performed a comprehensive pipeline analysis of BCMA targeting CAR-Ts in Multiple Myeloma indication.  PD-1/PD-L1 Combination StrategiesMalignant melanoma is a complex, multifactorial disease, which is responsible for up to 75% of skin cancer related deaths globally. With the US FDA approval of ipilimumab (CTLA-4 targeting agent) in 2011 for the treatment of advanced melanoma patients, clinical research intensity has gradually shifted towards Immune Checkpoint Inhibitors (ICIs) & their Combination agents. After the approval of nivolumab and pembrolizumab (both are PD-1 targeting agents), it is imperative to understand how PD-1/PD-L1 clinical landscape is evolving in melanoma.  Immune Checkpoint Inhibitors (ICIs) Pipeline LandscapeSCLC is an unforgiving, highly aggressive variant of lung cancer. It accounts for approximately 15% of the lung cancer cases globally and is also a major cause of cancer-related deaths. The chemotherapy has been the mainstay in SCLC management. While response rate to chemotherapy is high, notably, almost all patients relapse after few months (PFS is typically 4.0 - 5.5 months).  CAR-T Clinical Landscape ReportA lot has happened in the CAR-T field in the past 10 months since our last conference report on this technology. These include high-impact news such as EMA approval, and NICE recommendations for Kymriah and Yescarta. As the ASCO 2019 Annual Meeting is less than a month away, we are publishing an updated CAR-T clinical landscape report. This year, in addition to updating the industry funded CAR-T pipeline, we have included non-industry funded CAR-Ts, as well. We believe this addition will give you a better picture of the current CAR-T clinical landscape. To keep the scope manageable, we have limited our research to only those CAR-Ts that are conducted in US and/or EU location(s). We hope this report will help you get up to speed before the upcoming ASCO 2019 Annual Meeting.  Cervical Cancer Awareness SurveyWe are pleased to announce that our research work on Cervical Cancer Awareness in India has been accepted by the ESMO Scientific Committee. The study has been published as an abstract in ESMO 2017.
|
